Financing, Pharma

Annexon pulls in $34 million series A

Posted on 16 December 2014

Tags: ,

Annexon Bioscience has closed a $34 million Series A-1 to support the development of its lead candidate, ANX005, for the treatment of neurodegenerative and autoimmune disorders.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

 

The round was led by Novartis Venture Funds with participating investors Satter Investment Management, and Clarus Ventures.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

Print Friendly, PDF & Email

Leave a Reply